Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Hematologists who Treat Thrombocytopenias in the U.S.

Analysis of: Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma (content.nejm.org)
Velcade + classic Melphalan/ Prednisone  (MP) is better than MP alone. No surprise
Analysis of: Amgen Blood-Disorder Drug Gains Clearance (online.wsj.com)
Chronic ITP is not all that uncommon and becomes a quality of life issue with chronic steroid use as well as agents that are normaly used in neoplasia and even derivatives of male hormones.
Analysis of: Scientists Find Way to Create Red Blood Cells (online.wsj.com)
Advanced Cell Technology in Worcester, Mass., the University of Illinois at Chicago and the Mayo Clinic in Rochester, Minn. scientists say they've found an efficient way to make red blood cells from human embryonic stem cells. Impreesive!
Analysis of: Drug Makers’ Push Leads to Cancer Vaccines’ Fast Rise (www.nytimes.com)
Cervical cancer vaccines manufactured by Merck and Glaxo have been hyped, pushed and if the companies have their way, mandated by various states and organizations. (Who is benefiting? Patients or the politicians?) There are many unanswered questions but marketing and mandates press on!
Analysis of: Economic Evaluation of Sunitinib Malate for the First-Line Treatment of Metastatic Renal Cell Carcinoma (jco.ascopubs.org)
When using a model (of whose desin?) Pfizer's Sunitinib (Sutent) was found to be cost effective by Pfizer people? Surprise!!!
Analysis of: Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer (jco.ascopubs.org)
"The investigator-assessed objective response rate (complete and partial response), including both confirmed and unconfirmed responses, was 38% in the PF-3512676 plus chemotherapy arm and 19% in the chemotherapy-alone arm (P = .043)." In other words. IT MAY WORK!
Analysis of: Insurers Expect Health-Care Costs To Rise More Than 10% Next Year (online.wsj.com)
10% increase in medical spending when the overall cost of living is 1/2 of medical costs and we are happy??
Analysis of: UK Says Kidney Cancer Drugs Are Too Pricey (www.pharmalot.com)
Pfizer’s Sutent, Wyeth’s Torisel, Bayer’s Nexavar and Avastin, sold by Roche and Genentech have been deemed too expensive to be paid for by UK agencies
Analysis of: Salmonella Is Tested To Fight Cancer Cells (online.wsj.com)
Salmonella targeting cancer cells? In humans???
Analysis of: Panel Urges End to Prostate Screening at Age 75 (www.nytimes.com)
Since treatment may be worse than the disease it is being recommended that routine prostate cancer screening be stopped after the age of 75.

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next41 to 50 of 445

Analytics


Generated at 2009-01-07T13:00:17.563